

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5665994

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALLERGAN, INC.	11/30/2018
RECEIVING PARTY DATA	
Name:	ACLARIS THERAPEUTICS, INC.
Street Address:	640 LEE ROAD
City:	WAYNE
State/Country:	PENNSYLVANIA
Postal Code:	19087
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16380538
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	docketingpgh@pepperlaw.com
Correspondent Name:	PEPPER HAMILTON LLP
Address Line 1:	501 GRANT STREET, SUITE 300
Address Line 2:	UNION TRUST BUILDING
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15219-4429
ATTORNEY DOCKET NUMBER:	139883.02831
NAME OF SUBMITTER:	ANTONELLE M. PICCIRILLI
SIGNATURE:	/Antonelle M. Piccirilli/
DATE SIGNED:	08/13/2019
Total Attachments: 16	
source=Assignment_Allergen_Aclaris_2831#page1.tif	
source=Assignment_Allergen_Aclaris_2831#page2.tif	
source=Assignment_Allergen_Aclaris_2831#page3.tif	
source=Assignment_Allergen_Aclaris_2831#page4.tif	
source=Assignment_Allergen_Aclaris_2831#page5.tif	
source=Assignment_Allergen_Aclaris_2831#page6.tif	

source=Assignment_Allergen_Aclaris_2831#page7.tif
source=Assignment_Allergen_Aclaris_2831#page8.tif
source=Assignment_Allergen_Aclaris_2831#page9.tif
source=Assignment_Allergen_Aclaris_2831#page10.tif
source=Assignment_Allergen_Aclaris_2831#page11.tif
source=Assignment_Allergen_Aclaris_2831#page12.tif
source=Assignment_Allergen_Aclaris_2831#page13.tif
source=Assignment_Allergen_Aclaris_2831#page14.tif
source=Assignment_Allergen_Aclaris_2831#page15.tif
source=Assignment_Allergen_Aclaris_2831#page16.tif

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is dated as of November 30, 2018 (“Effective Date”), and is made by and between Allergan, Inc., a Delaware corporation (“Assignor”), and Aclaris Therapeutics, Inc., a Delaware corporation (“Assignee”). Each of Assignor and Assignee may be referenced herein as a “Party,” and collectively, the “Parties.”

WITNESSETH:

WHEREAS, pursuant to that certain Asset Purchase Agreement between Allergan Sales, LLC (“Seller”) and Assignee dated as of October 15, 2018 (the “Purchase Agreement”), Seller has agreed to (and cause its applicable Affiliates to) sell, convey, assign and transfer to Assignee, at the Closing, certain assets, including the Patents listed on Schedule A hereto (the “Assigned Patents”); and

WHEREAS, as a condition to the Closing, the Parties agreed to enter into this Agreement pursuant to which Assignor shall assign to Assignee all of Assignor’s right, title and interest in, to and under the Assigned Patents, as the case may be.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

1. Defined Terms; Interpretation. Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement. This Agreement shall be interpreted in accordance with the rules of construction set forth in Section 11.9 of the Purchase Agreement.

2. Assignment of Rights in Assigned Patents. Effective upon the Effective Date, Assignor hereby sells, conveys, assigns and transfers to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and interest in, to and under (a) the Assigned Patents, (b) all applications and registrations for the Assigned Patents, together with all non-provisionals, reissuances, continuations, continuations-in-part, divisions, revisions, extensions and reexaminations with respect thereto, and any other applications and patents claiming priority thereto and (d) any and all rights, benefits, privileges and proceeds under the Assigned Patents throughout the world, including (i) any claim by Assignor against Third Parties for past, present or future infringement of the Assigned Patents, and the right to sue for and collect the same for Assignee’s own use and enjoyment, all to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had the assignment not been made, (ii) the exclusive right to apply for, maintain and claim priority from all registrations, renewals or extensions thereof, (iii) the exclusive right to grant licenses or other interests therein, (iv) the right to claim priority in all countries in accordance with international law, (v) the right to collect royalties and proceeds in connection with any of the foregoing and (vi) to apply for, prosecute, and seek patents throughout the world in respect of any inventions to the extent fully supported by the Assigned Patents.

3. Recording. Assignor hereby requests the Commissioner of Patents and Trademarks and the corresponding entities or agencies in any other applicable countries to record

Assignee as the assignee and owner of the Assigned Patents, including any continuations, divisions, continuations-in part, registrations, reissues, reexaminations or extensions thereof, and to issue any and all letters patent of the United States thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

4. Assistance. Assignor shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Agreement. Furthermore, Assignor will, upon reasonable request, without further or additional consideration, but at the expense of Assignee, execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, such additional instruments, notices, releases, certificates, powers of attorney, assurances, bills of sale and other documents and do such further acts, assignments, transfers and other things, in each case, as reasonably necessary to transfer to Assignee the Assigned Patents, to vest and confirm in Assignee the legal title to the Assigned Patents, and to perfect Assignee's enjoyment of this grant.

5. Miscellaneous. This Agreement is executed and delivered pursuant to, is in accordance with, and is subject to, all of the representations, warranties, covenants and indemnities set forth in the Purchase Agreement, all of which shall survive the consummation of the transactions contemplated hereby on the basis and to the extent set forth in the Purchase Agreement. Nothing contained in this Agreement shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions set forth in the Purchase Agreement nor shall this Agreement reduce, expand or enlarge any remedies under the Purchase Agreement. In the event that any provision of this Agreement shall be construed to conflict with a provision in the Purchase Agreement, the terms of the Purchase Agreement shall control. This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission in .pdf, .tiff or any similar format), each of which shall be an original, but all of such counterparts together constitute one and the same instrument, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and assigns. This Agreement shall be governed in all respects, including validity, interpretation, construction, performance and effect, by the internal laws of the State of Delaware, without regard to its conflict of laws principles that would result in the application of the law of any other state or jurisdiction. This Agreement may not be waived or amended except by an instrument in writing signed on behalf of each of the Parties hereto.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the undersigned has executed this Patent Assignment Agreement as of the date first set forth above.

ASSIGNOR:

ALLERGAN, INC.

By: 

Name: Thomas Poché

Title: Vice President

[Signature Page to Patent Assignment Agreement]

PATENT
REEL: 050688 FRAME: 0280

IN WITNESS WHEREOF, the Assignee has executed this Patent Assignment Agreement as of the date first set forth above.

ASSIGNEE:

ACLARIS THERAPEUTICS, INC.

By: _____



Name: Neal Walker

Title: President & CEO

[Signature Page to Patent Assignment Agreement]

PATENT
REEL: 050688 FRAME: 0288

Schedule A
Assigned Patents

Non-Rhofade Assigned Patents

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
US	Provisional	Expired	61/443,210	2/15/2011			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
WO	PCT Application	Expired	PCT/US12/25068	2/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
US	Ordinary/Utility	Abandoned	13/396,165	2/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
AU	PCT National Phase	Pending	2012217858	8/15/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
BR	PCT National Phase	Pending	BR112013020770-1	8/14/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
CA	PCT National Phase	Published	2,827,373	8/14/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
CN	PCT National Phase	Abandoned	2012800179627	10/11/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
EP	PCT National Phase	Published	12705755.2	9/4/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
IN	PCT National Phase	Abandoned	7363/DELNP/2013	8/21/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
JP	PCT National Phase	Allowed	2013-554551	8/12/2013	6225030	10/13/2017	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
KR	PCT National Phase	Pending	10-2013-7024232	8/12/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
RU	PCT National Phase	Granted	2013141845	8/12/2013	2648439	3/26/2018	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
US	Continuation	Published	14/144,106	12/30/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
HK		Published	14105951	6/23/2014			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
JP	Divisional	Granted	2017-002106	1/10/2017	6389534	8/24/2018	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
AU	Divisional	Pending	2017202726	4/26/2017			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
CN	Divisional	Published	2017102800452	4/25/2017			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
JP	Divisional	Filed	2018-153450	8/17/2018			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
AU	PCT National Phase	Granted	2008322411	11/17/2008	2008322411	7/17/2014	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
IN	PCT National Phase	Abandoned	1098/MUMNP/2010	11/17/2008			COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
IL	PCT National Phase	Granted	205704	11/17/2008	205704	10/1/2015	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
JP	PCT National Phase	Granted	2010-534258	11/17/2008	5670196	12/26/2014	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
KR	PCT National Phase	Granted	10-2010-7013170	11/17/2008	10-2010-7013170	12/8/2015	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
MX	PCT National Phase	Allowed	MX/a/2010/005331	11/17/2008			COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
CN	PCT National Phase	Granted	200880116406 8/9	11/17/2008	ZL 200880116406.9	5/20/2015	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
US	Ordinary/Utility	Granted	12/272,253	11/17/2008	8,114,898	2/14/2012	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
HK		Abandoned	11100638.5	11/17/2008			COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
US	Provisional	Expired	60/988,564	11/16/2007			COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
WO	PCT Application	Expired	PCT/US08/083774	11/17/2008			COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
CA	PCT National Phase	Granted	2,703,109	11/17/2008	2,703,109	7/18/2017	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
EP	PCT National Phase	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
BR	PCT National Phase	Abandoned	PI0819075-5	11/17/2008			COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
US	Continuation	Granted	13/345,472	1/6/2012	8,673,953	3/18/2014	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.
US	Continuation	Granted	14/181,706	2/16/2014	9,265,761	2/23/2016	COMPOSITIONS AND METHODS OF TREATING PURPPURA	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
EP	Divisional	Published	14170999.8	6/2/2014			COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
DE	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
FR	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
GB	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
US	Continuation	Abandoned	14/505,100	10/2/2014			COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
JP	Divisional	Allowed	2014-214612	10/21/2014	5938082	5/20/2016	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
CN	Divisional	Allowed	201210033288 2/7	5/26/2004	102743380	8/12/2015	COMPOSITIONS AND METHODS OF TREATING PURPURA	Allergan, Inc.
US	Provisional	Expired	61/507,926	7/14/2011			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
WO	PCT Application	Abandoned	PCT/US12/46547	7/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
US	Ordinary/Utility	Abandoned	13/548,009	7/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Abandoned	2012281059	1/15/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
BR	PCT National Phase	Abandoned	BR112014000876-0	1/14/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
CA	PCT National Phase	Abandoned	2,841,632	1/13/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
CN	PCT National Phase	Abandoned	2012800444247	3/12/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
EP	PCT National Phase	Abandoned	12762684.4	1/14/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
IN	PCT National Phase	Abandoned	406/DELNP/2014	1/13/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
JP	PCT National Phase	Abandoned	2014-520339	1/14/2014			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
KR	PCT National Phase	Abandoned	10-2014-7003753	2/13/2014			GEL COMPOSITIONS OF	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
							OXYMETAZOLINE AND METHODS OF USE	
							GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	
RU	PCT National Phase	Abandoned	2014104559	2/11/2014				Allergan, Inc.

Rhofade Assigned Patents

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
US	Provisional	Expired	61/419,693	12/3/2010			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
WO	PCT Application	Expired	PCT/US11/62936	12/1/2011			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
TW	Ordinary/Utility	Granted	100144568	12/2/2011	IS33893	5/21/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
US	Ordinary/Utility	Granted	13/309,403	12/1/2011	8,883,838	11/11/2014	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc.
AU	PCT National Phase	Granted	2011336449	6/26/2013	2011336449	10/20/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
CA	PCT National Phase	Published	2,819,633	5/30/2013			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
EP	PCT National Phase	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
JP	PCT National Phase	Granted	2013-542183	5/31/2013	6030067	10/28/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
HK		Granted	14103376.2	4/2/2014	HK1190307	1/5/2018	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
US	Continuation	Published	14/521,094	10/22/2014			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
AU	Divisional	Abandoned	2016238909	10/6/2016			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
EP	Divisional	Published	16196317.8	10/28/2016			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
AT	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
BE	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
CH	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
CZ	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
DE	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
DK	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
ES	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
FR	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
GB	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
GR	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
IE	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
IT	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
NL	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
NO	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
PL	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
PT	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
RO	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
SE	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
TR	EPO Validated State	Granted	11794911.5	6/26/2013	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.
US	Provisional	Expired	62/010,838	6/11/2014			OXYMETAZOLINE CREAM FOR THE TREATMENT OF ERYTHEMA ASSOCIATED WITH ROSACEA	Allergan, Inc.
US	Provisional	Expired	62/069,624	10/28/2014			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
US	Ordinary/Utility	Granted	14/737,360	6/11/2015	9,801,857	10/31/2017	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
WO	PCT Application	Expired	PCT/US2015-035420	6/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
AU	PCT National Phase	Pending	2015274532	12/14/2016			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
CA	PCT National Phase	Published	2,951,725	12/8/2016			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
EP	PCT National Phase	Published	15738161.7	12/16/2016			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
MX	PCT National Phase	Pending	MX/a/2016/016400	12/8/2016			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
NZ	PCT National Phase	Pending	727233	12/7/2016			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
US	Ordinary/Utility	Granted	15/429,873	2/10/2017	9,974,773	5/22/2018	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
HK		Published	17110194.4	10/11/2017			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
							USES	
US	Continuation	Pending	15/984,918	5/21/2018			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Allergan, Inc.
US	Provisional	Expired	61/419,697	12/3/2010			CREAM COMPOSITIONS AND METHODS OF USE	Allergan, Inc.

PATENT

REEL: 050688 FRAME: 0480

RECORDED: 02/05/2018